Notice of Public Hearing

Pursuant to subsection E of § 54.1-3443, the Board of Pharmacy is giving notice of a public hearing to consider placement of chemical substances in Schedule I of the Drug Control Act and to consider removal of chemical substances in Schedule IV. The public hearing will be conducted at 9:06 a.m. on September 24, 2024. Instructions will be included in the agenda for the board meeting, also on September 24. Public comment may also be submitted electronically or in writing prior to September 24 to Caroline Juran, Executive Director of the Board of Pharmacy to caroline.juran@dhp.virginia.gov.

Pursuant to article § 54.1-3443(E), the following drugs will be placed in Schedule I to conform with federal scheduling actions taken from December 2023 to September 12, 2024:

• meta -fluorofentanyl ( N -(3-fluorophenyl)- N -(1-phenethylpiperidin-4-yl)propionamide);
• meta -fluoroisobutyryl fentanyl ( N -(3-fluorophenyl)- N -(1-phenethylpiperidin-4-yl)isobutyramide);
• para -methoxyfuranyl fentanyl ( N -(4-methoxyphenyl)- N -(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
• 3-furanyl fentanyl (N -(1-phenethylpiperidin-4-yl)- N -phenylfuran-3-carboxamide);
• 2′,5′-dimethoxyfentanyl (N -(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)- N -phenylpropionamide);
• isovaleryl fentanyl (3-methyl-N -(1-phenethylpiperidin-4-yl)- N -phenylbutanamide);
• ortho -fluorofuranyl fentanyl ( N -(2-fluorophenyl)- N -(1-phenethylpiperidin-4-yl)furan-2-carboxamide); 
• para -methylcyclopropyl fentanyl ( N -(4-methylphenyl)- N -(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
• Methyl 2-[[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (Other names: 4F-MDMB-BUTICA; 4F-MDMB-BICA);
• 5-Pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-one (Other name: CUMYL-PEGACLONE; SGT-151);
• Ethyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate (Other names: 5F-EDMB-PICA; 5F-EDMB-2201); and 
• 2-(4-ethoxybenzyl)-5-nitro-1-(2-(piperidin-1-yl)ethyl)-1H -benzimidazole (commonly known as either N -piperidinyl etonitazene or etonitazepipne).